Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Drug-drug Interaction Between Telmisartan, Amlodipine and Hydrochlorothiazide

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03889145
Recruitment Status : Completed
First Posted : March 26, 2019
Last Update Posted : March 26, 2019
Sponsor:
Information provided by (Responsible Party):
IlDong Pharmaceutical Co Ltd

Brief Summary:
A randomized, open-label, single dose, 3-way crossover study to evaluate the drug-drugs interaction between Telmisartan, Amlodipine and Hydrochlorothiazide in healthy male volunteers

Condition or disease Intervention/treatment Phase
Healthy Drug: Telmisartan 80mg Drug: Amlodipine10mg Drug: Hydrochlorothiazide Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-label, Single Dose, 3-way Crossover Study to Evaluate the Drug-drugs Interaction Between Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers
Actual Study Start Date : December 19, 2013
Actual Primary Completion Date : February 19, 2014
Actual Study Completion Date : February 19, 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Drug Reactions

Arm Intervention/treatment
Active Comparator: Telmisartan, Amlodipine Drug: Telmisartan 80mg
Telmisartan 80mg

Drug: Amlodipine10mg
Amlodipine 10mg

Active Comparator: Hydrochlorothiazide Drug: Hydrochlorothiazide
Hydrochlorothiazide 25mg

Experimental: Telmisartan, Amlodipine, Hydrochlorothiazide Drug: Telmisartan 80mg
Telmisartan 80mg

Drug: Amlodipine10mg
Amlodipine 10mg

Drug: Hydrochlorothiazide
Hydrochlorothiazide 25mg




Primary Outcome Measures :
  1. AUClast [ Time Frame: Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)] ]
  2. Cmax [ Time Frame: Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)] ]

Secondary Outcome Measures :
  1. AUCinf [ Time Frame: Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)] ]
  2. Tmax [ Time Frame: Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)] ]

Other Outcome Measures:
  1. t1/2 [ Time Frame: Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)] ]
  2. CL/F [ Time Frame: Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)] ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male volunteers aged 20 to 55 years
  • Subjects who have 17.5 ~ 30.5 kg/m2 body mass index (BMI) and body weight that is more than 55kg
  • Subjects who have no congenital or chronic disease within the last 3 years and have no pathological symptoms or findings as a result of medical examination.
  • Suitable subject who is determined by laboratory tests such as hematology tests, blood chemistry, urinalysis test according to the characteristics of the drug and screening tests such as electrocardiography(ECG) test.
  • Subject who fully understand the clinical trials after in-depth explanation given prior to the clinical study, decided to join the clinical trials by their will and signed consent form which approved by Chonbuk National University Hospital Institutional Review Board(IRB).

Exclusion Criteria:

  • Subjects who have a history of blood, kidneys, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurological or allergic diseases that is clinically significant (Except untreated asymptomatic seasonal allergies at the time of administration)
  • Subjects who have a history of gastrointestinal disease or gastrointestinal surgery which can affect drug absorption.
  • Subjects who drink Alcohol > 210g/week within 6 months prior to the screening.
  • Subjects who involved in other clinical trials within two months before the first dose medication characters.
  • Subjects who show Systolic Blood Pressure ≤100 or ≥150 mmHg or Diastolic Blood Pressure ≤60 or ≥100 mmHg at screening
  • Subjects who had alcohol or drug abuse within one year before the screening
  • Subjects who took medication of drug-metabolizing enzymes that are known to significantly induce or inhibit within 30 days
  • Subjects who smoke 20 cigarettes or more a day
  • Subjects who take medicine within 10 days before the first investigational product administration.
  • Subject who done the whole blood donation within two months or component blood donation within 1 month within 1 month prior to the first dosing.
  • Subject who can increase risk due to clinical test and administration of drugs or has severe grade / chronic medical, mental condition or abnormal laboratory result that may interfere with the analysis of test results.
  • Subjects with serious history of hypersensitivity or allergy to investigational product.
  • Subjects with severe hepatic impairment or Gallbladder Disease.
  • Subject with hereditary angioedema or a history of angioedema when treated with ACE(Angiotensin-Converting enzyme) inhibitor or ARB(Angiotensin II Receptor Blocker) therapy
  • Subjects who take combination medication with aliskiren in Diabetic patient or moderate to severe renal insufficient subjects (glomerular filtration rate<60mL/min/1.73m2)
  • Subjects with severe hepatic impairment
  • Subjects who have severe aortic stenosis
  • Subjects with acute or severe renal failure
  • Subjects with hyponatremia or hypokalemia
  • Subjects with Addison's disease
  • Subjects with hypercalcemia
  • Subjects who have galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
  • Subjects who are unwilling or unable to comply with the Lifestyle guidelines described in this protocol
  • Subject who are inadequate for this study to participate judged by investigator

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: IlDong Pharmaceutical Co Ltd
ClinicalTrials.gov Identifier: NCT03889145     History of Changes
Other Study ID Numbers: ID-TAH-1301
First Posted: March 26, 2019    Key Record Dates
Last Update Posted: March 26, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hydrochlorothiazide
Amlodipine
Telmisartan
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Vasodilator Agents
Diuretics
Natriuretic Agents
Sodium Chloride Symporter Inhibitors
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists